Biomarkers in preclinical Alzheimer's disease

Current Opinion in Investigational Drugs

Volumn 7, Issue 7, 2006, Pages 600-607

  Chong, Mei Sian ^a   Lim, Wee Shiong ^a   Sahadevan, Suresh ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

amyloid1 42; A ; Alzheimer's disease; Biological markers; Cerebrospinal fluid; Early diagnosis; Magnetic resonance imaging; Positron emission tomography; Tau proteins

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ISOPROSTANE; MILAMELINE; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE C 11; PLACEBO; TAU PROTEIN; TRACER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; COGNITION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DRUG RESPONSE; EARLY DIAGNOSIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; LUMBAR PUNCTURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; VOLUMETRY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 33745795370     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Wimo A, Winblad B, Aguero-Torres H, von Strauss E: The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord (2003) 17(2):63-67.
2. Price JL, Morris JC: Tangles and plaques in nondemented aging and "preclinical" Alzheimer disease. Ann Neurol (1999) 45(3):358-368.
3. Morris JC, Storandt M, Miller JP, McKeet DW, Price JL, Rubin EH, Berg L: Mild cognitive impairment represents early stage Alzheimer's disease. Arch Neurol (2001) 58(3):397-405.
4. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 256(3):183-194.
5. Peterson RC, Smith GE, Waring SC, Ivnik RJ, Tangalos E, Kokmen E: Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol (1999) 56(3):303-308.
6. Ritchie K, Touchon J: Mild cognitive impairment: Conceptual basis and current nosological status. Lancet (2000) 365(9199):226-228.
7. No authors listed: Consensus report of the Working Group on: "Molecular and biochemical markers of Alzheimer's disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging (1998) 19(2):109-116.
8. Klunk WE: Biological markers of Alzheimer's disease. Neurobiol Aging (1998) 19(2):145-147.
9. Blennow K, Hampal H: CSF markers for incipient Alzheimer's disease. Lancet Neurology (2003) 2(10):605-813.
10. Arai H, Nakagawa T, Kosaka Y, Higuchi M, Matsui T, Okamura N, Tashiro M, Sasaki H: Elevated cerebrospinal fluid tau protein as a predictor of dementia in memory-impaired patients. Alzheimer Res (1997) 3:211-213.
11. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K: Cerebrospinal fluid levels of total-tau, phosphor-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand (2003) 107(suppl 179):47-51.
12. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltlang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Moller HJ et al: Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 9(7):705-710.
13. 1-42 in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol (2001) 172(2):433-436.
14. Arai H, Idhiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Kohno H, Sasaki H et al: CSF phosphorylated tau protein and mild cognitive impairment: A prospective study. Exp Neurol (2000) 166(1):201-203.
15. Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, McCulloch C, Ptok U, Heun R, Andreasen N et al: CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 59(4):627-629.
16. Riemenschneider M, Lautenschlager N, Wegenpfeil S, Diehl J, Drzezga A, Kurz A: Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol (2002) 59(11):1729-1734.
17. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K: Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett (1999) 273(1):5-8.
18. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology (2005) 64(7):1294-1297.
19. Zetterberg H, Wahlund LO, Blennow K: Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett (2003) 352(1):67-69.
20. Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P: Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers. Mech Ageing Dev (2006) 127(2):129-132.
21. de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W, Saint Louis LA et al: Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett (2002) 333(3):183-186.
22. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM et al: Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2008) 27(3):394-401.
23. deToledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, Wuu J, Turner DA: MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging (2004) 25(9):1197-1203.
24. Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, Beckett LA, deToledo-Morrell L: MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging (2001) 22(5):747-754.
25. Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS: Use of structural magnetic resonance imaging to predict who will got Alzheimer's disease. Ann Neurol (2000) 47(4):430-439.
26. Jack CR Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E: Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 52(7):1397-1403.
27. Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, Tanzi R, Jones K, Albert MS: MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology (2002) 58(8):1188-1196.
28. Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles J: Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Naurosurg Psychiatry (2002) 72(4):491-497.
29. Korf ES, Wahlund LO, Visser PJ, Scheltens P: Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology (2004) 63(1):94-100.
30. Visser PJ, Scheltens P, Verhey FR, Schmand B, Launer LJ, Jolles J, Jonker C: Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol (1999) 246(6):477-485.
31. Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG et al: Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 62(4):591-600.
32. Jack CR Jr, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, Ivnik RJ, Tangalos EG, Petersen RC: Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology (2005) 65(8):1227-1231.
33. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Weigand SD, O'Brien PC, Shiung MM, Smith GE, Ivnik RJ, Tangalos EG, Jack CR Jr: DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology (2005) 64(5):902-904.
34. Pennanen C, Testa C, Laakso MP, Hallikainen M, Helkala EL, Hanninen T, Kivipelto M, Kononen M, Nissinen A, Tervo S, Vanhanen M et al: A voxel-based morphometry study on mild cognitive impairment. J Neurol Neurosurg Psychiatry 76(1):11-14.
35. Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, Desgranges B, Baron JC: Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: A longitudinal MRI study. Neuroimage (2005) 27(4):934-946.
36. Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL: Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology (2005) 64(6):1032-1039.
37. Nestor PJ, Sheltens P, Hodges JR: Advances in the early detection of Alzheimer's disease. Nat Med (2004) 10(suppl):S34-S41.
38. Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, Albert MS: Preclinical prediction of Alzheimer's disease using SPECT. Neurology (1998) 50(6):1563-1571.
39. Cabranes JA, De Juan R, Encinas M, Marcos A, Gil P, Fernandez C, De Ugarte C, Barabash A: Relevance of functional neuroimaging in the progression of mild cognitive impairment. Neurol Res (2004) 26(5):496-501.
40. Huang C, Wahlund LO, Svensson L, Winblad B, Julin P: Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurology (2002) 2:9.
41. Hirao K, Ohnishi T, Hirata Y, Yamashita F, Mori T, Moriguchi Y, Matsuda H, Nemoto K, Imabayashi E, Yamada M, Iwamoto T et al: The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage (2005) 28(4):1014-1021.
42. Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, Nordberg A: Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport (2001) 12(4):851-855.
43. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC: Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology (2003) 60(8):1374-1377.
44. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, Cappa S, Lenz O, Ludecke S, Marcone A, Mielke R et al: Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol (2005) 62(11):1728-1733.
45. Modrego PJ, Fayed N, Pina MA: Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry (2005) 162(4):667-675.
46. Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, Dale AM, Stern CE, Blacker D, Albert MS, Sperling RA: Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol (2004) 56(1):27-35.
47. Teunissen CE, de Vente J, Steinbusch HW, De Bruijin C: Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging (2002) 23(4):485-508.
48. Frank RA, Galasko D, Hempel H, Hardy J, de Leon W, Mehta PD, Rogers J, Siemers E, Trojanowski JQ: Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group. Neurobiol Aging (2003) 24(4):521-536.
49. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, Capurso SA, Pietrarossa G, Santamato V, Capurso A, Panza F: Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta (2006) 364(1-2):91-112.
50. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC: Impact of APOE in mild cognitive impairment. Neurology (2004) 63(10):1898-1901.
51. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K: APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42. Neurology (2004) 62(11):2116-2118.
52. Buerger K, Teipel SJ, Zinkowski R, Sunderland T, Andreasen N, Blennow K, Ewers M, DeBernardis J, Shen Y, Kerkman D, Du Y et al: Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment. Neurosci Lett (2005) 39(1-2):48-50.
53. El Fakhri G, Kijewski MF, Johnson KA, Syrkin G, Killany RJ, Becker JA, Zimmerman RE, Albert MS: MRI-gulded SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease. Arch Neurol (2003) 60(8):1066-1072.
54. Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H: Combined analysis of CSF tau levels and [(123)l]lodoamphetamine SPECT in mild cognitive impairment: Implications for a novel predictor of Alzheimer's disease. Am J Psychiatry (2002) 159(3):474-476.
55. Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schutz C, Burger K, Dodel R, Du Y, Moller HJ, Bergmann A, Hempel H: Decreased serum amyloid β (1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β (1-42) peptide. Biol Psychiatry (2005) 57(7):813-816.
56. Csernansky JG, Wang L, Swank J, Miller JP, Gado M, McKeel D, Miller MI, Morris JC: Preclinical detection of Alzheimer's disease: Hippocampal shape and volume predict dementia onset in the elderly. Neuroimage (2005) 25(3):783-792.
57. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B et al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 55(3):306-319.
58. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA: Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 25(11):1528-1547.
59. 42 in humans. Ann Neurol (2006) 69(3):512-519.
60. Glabe CG, Kayed R: Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology (2006) 66(2 Suppl 1):S74-S78.
61. Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ. Amyloid-β immunotherapy for the prevention and treatment of Alzheimer disease: Lessons from mice, monkeys and humans. Rejuv Res (2006) 9(1):77-84.
62. Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V: Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci (2002) 23(Suppl2):S95-S96.
63. Stefanova E, Blennow K, Almkvist O, Hellstrom-Lindahl E, Nordberg A. Cerebral glucose metabolism, cerebrospinal fluid-β-amylold 1-42 (CSF-Aβ42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett (2003) 338(2):159-163.
64. Moriearty PL, Seubert P, Galasko D, Markwell S, Unni L, Vicari S, Becker RE: Effects of time and cholinesterass inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease. Methods Find Exp Clin Pharmacol (1999) 21(8):549-554.
65. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM et al: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 64(9):1553-1562.
66. Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O'Brien PC, Cha R, Knopman D et al: MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology (2003) 60(2):253-260.
67. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry (2003) 160(11):2003-2011.
68. 1H-MRS) in Alzheimer's disease: Changes after treatment with xanomeline: An M1 selective cholinergic agonist. Am J Psychiatry (1997) 154(10):1459-1461.
69. Frederick B, Satlin A, Wald LL, Hennan J, Bodick N, Renshaw PF: Brain proton magnetic resonance spectroscopy in Alzheimer disease: Changes after treatment with xanomeline. Am J Geristr Psychiatry (2002) 10(1):81-88.
70. Csernansky JG, Wang L, Miller P, Galvin JE, Morris JC: Neuroanatomical predictors of response to doneperil therapy in patients with dementia. Arch Neurol (2005) 62(11):1718-1722.
71. Borroni B, Colciaghi F, Pastorino L, Pettenati C, Cottini E, Rozzini L, Monastero R, Lenzi GL, Cattabeni F, Di Luca M, Padovani A: Amyloid precursor protein in platelets of patients with Alzheimer disease. Arch Neurol (2001) 58(3):442-446.
72. Basun H, Nilsberth C, Eckman C, Lannfelt L, Younkin S: Plasma levels of Aβ42 and Aβ40 in Alzheimer patients during treatment with acetylcholinesterase inhibitor Tacrine. Dement Geriatr Cogn Disord (2002) 14(3):156-160.
73. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M: Effects of Aβ Immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 64(9):1563-1572.
74. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E et al: Vitamin E and donepezil for the treatment of mild cognitive treatment. N Engl J Med (2005) 352(23):2379-2388.
75. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN: Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: Power calculations and estimates of sample size to detect treatment effects. Arch Neurol (2000) 57(3):339-344.
76. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC: Measuring atrophy in Alzheimer disease: A serial MRI study over 6 and 12 months. Neurology (2005) 65(1):119-124.